Double celebration for TopiVert and Sygnature Discovery as two drug candidates begin clinical trials
Sygnature Discovery | March 29, 2017
One of Sygnature Discovery’s long-term clients, TopiVert Pharma, has recently initiated clinical trials with TOP1288 and TOP1630. Both compounds were first synthesised at Sygnature during the successful collaboration. TOP1288 and TOP1630 are Narrow Spectrum Kinase Inhibitors (NSKIs).